Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy

PLoS One. 2013;8(1):e54531. doi: 10.1371/journal.pone.0054531. Epub 2013 Jan 18.

Abstract

Targeted radiotherapies maximize cytotoxicty to cancer cells. In vivo α-generator targeted radiotherapies can deliver multiple α particles to a receptor site dramatically amplifying the radiation dose delivered to the target. The major challenge with α-generator radiotherapies is that traditional chelating moieties are unable to sequester the radioactive daughters in the bioconjugate which is critical to minimize toxicity to healthy, non-target tissue. The recoil energy of the (225)Ac daughters following α decay will sever any metal-ligand bond used to form the bioconjugate. This work demonstrates that an engineered multilayered nanoparticle-antibody conjugate can deliver multiple α radiations and contain the decay daughters of (225)Ac while targeting biologically relevant receptors in a female BALB/c mouse model. These multi-shell nanoparticles combine the radiation resistance of lanthanide phosphate to contain (225)Ac and its radioactive decay daughters, the magnetic properties of gadolinium phosphate for easy separation, and established gold chemistry for attachment of targeting moieties.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Alpha Particles
  • Animals
  • Antibodies / administration & dosage
  • Chelating Agents / chemistry
  • Female
  • Gold / chemistry*
  • Gold / pharmacology
  • Humans
  • Immunoconjugates / administration & dosage
  • Lanthanum / chemistry*
  • Lanthanum / pharmacology
  • Metal Nanoparticles* / administration & dosage
  • Metal Nanoparticles* / chemistry
  • Mice
  • Mice, Inbred BALB C
  • Phosphates / chemistry*
  • Phosphates / pharmacology
  • Radiotherapy*
  • Tissue Distribution

Substances

  • Antibodies
  • Chelating Agents
  • Immunoconjugates
  • Phosphates
  • lanthanide phosphate
  • Lanthanum
  • Gold

Grants and funding

Research supported in part by the Isotope Production/Distribution Program, Office of Nuclear Physics of the U.S. Department of Energy (DOE), and under a DOE Nuclear Energy University Program Graduate Fellowship. The work was also supported by the University of Tennessee, Graduate School of Medicine through funding of the cancer imaging and tracer development program. A portion of this research was conducted at the Center for Nanophase Materials Sciences, which is sponsored at Oak Ridge National Laboratory by the Office of Basic Energy Sciences, U.S. Department of Energy. ORNL is managed by UT-Battelle, LLC, for the U. S. Department of energy under contract DE-AC05-00OR22725. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.